Guardant Health Inc., a leader in precision oncology, announced the commencement of patient enrollment in the National Cancer Institute's $(NCI)$ Vanguard Study. This study evaluates Guardant Health's Shield Multi-Cancer Detection $(MCD)$ test, which is under review by the U.S. Food and Drug Administration (FDA) as part of the NCI's investigational device exemption $(IDE)$. The Vanguard Study, a critical step in cancer detection research, aims to enroll up to 24,000 participants to assess the feasibility of using MCD tests in future trials. Conducted by the Cancer Screening Research network, it seeks to determine the effectiveness of these tests in early cancer detection and reducing cancer mortality.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。